At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Amrubicindrug
Likely dose
Amrubicin 35 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
In Brief
A Phase 2 clinical trial evaluating Amrubicin for Thymoma and 2 related conditions. Completed, enrolled 33 participants across 2 sites.
Detailed Summary
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for thymic cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThymoma, Thymus Cancer, Thymic Carcinoma
CountriesUnited States
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJun 2011
Primary CompletionJul 2014
Study CompletionDec 2018
TodayJul 2026
First PostedJun 2, 2011
Enrollment StartJun 1, 2011
Primary CompletionJul 1, 2014
Study CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.1 years ago
Interventions
Amrubicindrug
35 mg/m2; IV on days 1-3 each 3 week cycle